Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:ERAS NYSE:OGN NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.69+3.1%$5.69$1.60▼$7.18$924.67M1.222.55 million shs2.01 million shsERASErasca$10.12-2.7%$15.68$1.06▼$24.28$3.15B0.687.26 million shs3.13 million shsOGNOrganon & Co.$13.35+0.2%$8.00$5.69▼$13.44$3.50B1.578.22 million shs6.77 million shsTNGXTango Therapeutics$23.02-2.0%$20.17$1.07▼$28.41$3.32B1.223.29 million shs1.51 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-3.41%-5.96%-7.85%-3.66%+226.63%ERASErasca-4.59%-2.35%-39.04%-15.38%+748.98%OGNOrganon & Co.-0.45%+0.60%+118.13%+62.55%+52.62%TNGXTango Therapeutics-0.59%+8.60%+18.59%+87.69%+1,941.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.69+3.1%$5.69$1.60▼$7.18$924.67M1.222.55 million shs2.01 million shsERASErasca$10.12-2.7%$15.68$1.06▼$24.28$3.15B0.687.26 million shs3.13 million shsOGNOrganon & Co.$13.35+0.2%$8.00$5.69▼$13.44$3.50B1.578.22 million shs6.77 million shsTNGXTango Therapeutics$23.02-2.0%$20.17$1.07▼$28.41$3.32B1.223.29 million shs1.51 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-3.41%-5.96%-7.85%-3.66%+226.63%ERASErasca-4.59%-2.35%-39.04%-15.38%+748.98%OGNOrganon & Co.-0.45%+0.60%+118.13%+62.55%+52.62%TNGXTango Therapeutics-0.59%+8.60%+18.59%+87.69%+1,941.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.57Moderate Buy$17.00198.77% UpsideERASErasca 2.50Moderate Buy$17.8876.63% UpsideOGNOrganon & Co. 1.57Reduce$11.40-14.57% DownsideTNGXTango Therapeutics 2.77Moderate Buy$22.44-2.50% DownsideCurrent Analyst Ratings BreakdownLatest ANNX, OGN, TNGX, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2026OGNOrganon & Co. Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$5.00 ➝ $14.004/27/2026TNGXTango Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/27/2026ERASErasca Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $30.004/27/2026TNGXTango Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $40.004/20/2026ANNXAnnexon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/14/2026OGNOrganon & Co. Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/2/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.003/27/2026TNGXTango Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/AERASErascaN/AN/AN/AN/A$1.05 per shareN/AOGNOrganon & Co.$6.22B0.56$5.75 per share2.32$3.44 per share3.88TNGXTango Therapeutics$62.38M53.23N/AN/A$2.57 per share8.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.33%-76.96%5/11/2026 (Estimated)ERASErasca-$124.55M-$0.44N/AN/AN/AN/A-34.48%-28.74%5/12/2026 (Estimated)OGNOrganon & Co.$187M$0.9314.353.881.243.99%99.95%6.22%N/ATNGXTango Therapeutics-$101.59M-$0.87N/AN/AN/A-151.15%-50.30%-36.25%5/11/2026 (Estimated)Latest ANNX, OGN, TNGX, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ERASErasca-$0.19N/AN/AN/AN/AN/A5/11/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/11/2026Q1 2026TNGXTango Therapeutics-$0.32N/AN/AN/A$0.58 millionN/A4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion3/30/2026Q4 2025ANNXAnnexon-$0.32-$0.28+$0.04-$0.28$3.25 millionN/A3/12/2026Q4 2025ERASErasca-$0.11-$0.10+$0.01-$0.10N/AN/A3/5/2026Q4 2025TNGXTango Therapeutics-$0.31-$0.29+$0.02-$0.29$0.56 millionN/A2/12/2026Q4 2025OGNOrganon & Co.$0.73$0.63-$0.10-$0.79$1.52 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ALatest ANNX, OGN, TNGX, and ERAS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/20262/12/2026OGNOrganon & Co.quarterly$0.021.01%2/23/20262/23/20263/12/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A5.685.68ERASErascaN/A10.0410.04OGNOrganon & Co.9.471.971.23TNGXTango TherapeuticsN/A16.3216.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AERASErasca67.78%OGNOrganon & Co.77.43%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%ERASErasca14.40%OGNOrganon & Co.1.62%TNGXTango Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60162.51 million143.22 millionOptionableERASErasca120310.97 million266.19 millionOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionableTNGXTango Therapeutics90144.24 million134.87 millionOptionableANNX, OGN, TNGX, and ERAS HeadlinesRecent News About These CompaniesTango Therapeutics (NASDAQ:TNGX) Insider Sells $573,210.00 in StockMay 8 at 4:48 AM | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 27,000 SharesMay 6 at 6:03 AM | insidertrades.comAdam Crystal Sells 27,000 Shares of Tango Therapeutics (NASDAQ:TNGX) StockMay 5 at 8:09 PM | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Stock Price Up 7.1% - Time to Buy?May 4, 2026 | marketbeat.comTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comTango Therapeutics (TNGX) Expected to Announce Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comWhy this CEO is confident his drug can top 'unprecedented' pancreatic cancer resultsApril 30, 2026 | msn.comTango Therapeutics (NASDAQ:TNGX) Trading Down 9.7% - Here's What HappenedApril 29, 2026 | marketbeat.comTango Therapeutics (TNGX) price target increased by 11.68% to 24.38April 28, 2026 | msn.comStifel Nicolaus Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock PriceApril 27, 2026 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 25, 2026 | marketbeat.com354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham IncApril 21, 2026 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Reaches New 1-Year High - Should You Buy?April 20, 2026 | marketbeat.comIs Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines?April 20, 2026 | finance.yahoo.comTango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 38,460 SharesApril 17, 2026 | insidertrades.comInsider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 38,460 Shares of StockApril 16, 2026 | marketbeat.comTango Therapeutics Sub, Inc: Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatApril 16, 2026 | finanznachrichten.deTudor Investment Corp ET AL Acquires New Holdings in Tango Therapeutics, Inc. $TNGXApril 16, 2026 | marketbeat.comTango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatApril 15, 2026 | globenewswire.comTango Therapeutics (NASDAQ:TNGX) Reaches New 52-Week High - Here's What HappenedApril 14, 2026 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Shares Gap Up - Time to Buy?April 13, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANNX, OGN, TNGX, and ERAS Company DescriptionsAnnexon NASDAQ:ANNX$5.69 +0.17 (+3.08%) Closing price 04:00 PM EasternExtended Trading$5.72 +0.03 (+0.53%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Erasca NASDAQ:ERAS$10.12 -0.28 (-2.69%) Closing price 04:00 PM EasternExtended Trading$10.16 +0.04 (+0.42%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Organon & Co. NYSE:OGN$13.34 +0.03 (+0.19%) Closing price 03:58 PM EasternExtended Trading$13.29 -0.06 (-0.43%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Tango Therapeutics NASDAQ:TNGX$23.02 -0.46 (-1.96%) Closing price 04:00 PM EasternExtended Trading$23.02 0.00 (0.00%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
